Articles

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA;
Université Paris Diderot and Hôpital Saint-Louis AP-HP, Paris
Alexion Pharmaceuticals, Inc., Boston, MA,
Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen,
Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples
Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA;
Department of Haematology, St James's University Hospital, Leeds,
Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA;
Clinical Haematology, Royal Melbourne Hospital, Melbourne;
The Catholic University of Korea, College of Medicine, Seoul,
Department of Haematological Medicine, King College Hospital, London,
Alexion Pharmaceuticals, Inc., Boston, MA,
Alexion Pharmaceuticals, Inc., Boston, MA,
Alexion Pharmaceuticals, Inc., Boston, MA,
Alexion Pharmaceuticals, Inc., Boston, MA, USA;
Alexion Pharmaceuticals, Inc., Boston, MA
Department of Haematology, St James's University Hospital, Leeds
German Red Cross Blood Transfusion Service, Baden-Wurttemberg-Hessen and University Hospital Ulm
Vol. 106 No. 1 (2021): January, 2021 https://doi.org/10.3324/haematol.2019.236877